UNSPSC 51263172: Tertatolol hydrochloride

This classification denotes a beta-adrenergic blocking agent C16H25NO2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9SDH60Z1NO, chemically known as 2-propanol, 1-((3,4-dihydro-2h-1-benzothiopyran-8-yl)oxy)-3-((1,1-dimethylethyl)amino)-, hydrochloride (1:1), but more generally known as tertatolol hydrochloride, which bears US NIH Compound Identifier 161777. European Medicines Agency schedules Tertatolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32680.

Most nations, for tariff and trade purposes, schedule tertatolol hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, TERTATOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)(C)NCC(COC1CCCC2C1SCCC2)O.CL.

UNSPSC 51263172 Tertatolol hydrochloride is a Commodity code that in current state and local procurement activity does not map to the pharmaceutical product its name suggests. The recent opportunities posted under this code involve naloxone procurement and therapeutic pharmacy program management — neither of which represents tertatolol hydrochloride, a beta-blocker medication. The mismatch between code assignment and actual scope signals either a cataloging error or misalignment in how the issuing bodies tagged their solicitations. State and local governments buying under this code appear to be health agencies, county health departments, and state human services commissions seeking access to emergency medications, drug deactivation systems, and pharmacy benefit management services rather than the specific cardiovascular pharmaceutical the code nominally describes.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with response due July 26, 2023 — a date that appears to be a data error in the source. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program serving state employee health plans and self-insured groups, with no formal evaluation criteria or timeline specified at the information-gathering stage. The code shows sparse and geographically limited recent activity concentrated in Texas and Florida. Given the mismatch between the code's nominal pharmaceutical scope and the emergency medicine and pharmacy program management work actually being solicited, firms pursuing opportunities under this code should verify issuer intent and actual product requirements before responding, as the code assignment may not reliably predict future procurement needs.